A Study to Assess the Safety of TPM502 in Adults With Celiac Disease

Topas Therapeutics

Status and phase

Completed

Phase 2

Conditions

Celiac Disease

Treatments

Drug: TPM502

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05660109

TCeD21

Details and patient eligibility

About

The goal of this clinical trial is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease. The main questions it aims to answer are:

if TPM502 is safe and well tolerated
if TPM502 can induce modifications in parameters indicating that it may induce tolerance to gluten

Participants will:

undergo 1-day gluten challenge during screening and after administration of TPM502 or placebo.
receive 2 infusions of TPM502 or placebo, 2 weeks apart

Full description

This is a multi center, double-blind, randomized, placebo-controlled Phase 2a study to evaluate the safety, tolerability, and PD effects of two infusions of TPM502 in adult patients diagnosed with CeD.

The patient´s participation in the study comprises 3 phases: screening period, treatment period and follow-up period.

Patients fulfilling the eligibility criteria will be randomized to receive two infusions of TMP502 (or placebo) at the same dose level. Patients will undergo a second GC one week after the second infusion of TPM502.

The study includes 4 cohorts of patients, each cohort will receive escalating doses of TPM502 (or placebo). Upon completion of the 3rd cohort, a lower dose can be investigated, if deemed relevant.

Enrollment

28 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Availability of a documented biopsy-confirmed diagnosis of CeD OR documented tissue transglutaminase >10x ULN and documented positive IgA anti-endomysial antibody (EMA) at time of CeD diagnosis (as per local guidelines)
Serum anti-tissue transglutaminase 2 immunoglobin A antibodies within normal range (i.e., <15 U/mL) at screening
Serum IL-2 levels (AUC1-6h) above a pre-defined threshold following the GC at screening
Patients must have been on GFD for ≥ 6 months
Patients must have well-controlled CeD, defined as mild or with no ongoing signs or symptoms felt to be related to active CeD, as per investigator's assessment
HLA-DQ2.5 positive

Exclusion criteria

Known or suspected refractory CeD (refractory CeD type I or II)
Known intolerable symptoms following previous GCs, as per investigator's assessment
HLA DQ8 positive
Any active gastrointestinal disease such as gastroesophageal reflux disease, esophagitis or peptic ulcer, microscopic colitis, or irritable bowel syndrome, which in the opinion of the investigator might interfere with the assessment of the symptoms related to CeD
Known history of or active Crohn's disease, ulcerative colitis, or ulcerative jejunitis
Known wheat allergy
Known hypersensitivity to i.v. iron preparations or any other excipients present in the reconstituted TPM502 or placebo